Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test formulation (Treatment A) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

NCT00759902
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 21, 2026, 2:26 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

NCT01844323
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

NCT07130097
View directory record Official record
Conditions
Healthy Participant
Interventions
PF-07220060
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

NCT04310007
View directory record Official record
Conditions
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
611
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste

NCT07419672
View directory record Official record
Conditions
Dental Caries
Interventions
Negative Control Treatment Slurry (Fluoride-Free), Active Comparator Fluoride Treatment (0.454% SnF), Test Fluoride Treatment (0.454% SnF) (Investigational Toothpaste)
Drug
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Noblesville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

NCT05955872
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
VX-147
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

The Cultural Formulation Interview-Engagement Aid

NCT03044145
View directory record Official record
Conditions
Communication, Adherence, Patient
Interventions
The Cultural Formulation Interview-Engagement Aid in Project 1, The Cultural Formulation Interview-Engagement Aid Revised for Project 2, Treatment as usual for Project 2
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Iontophoretic Application of Terbinafine Gel to the Large Toe Nail

NCT00768768
View directory record Official record
Conditions
Onychomycosis
Interventions
Electrokinetic Transungual System (ETS) - Terbinafine Gel, ETS-Terbinafine Gel
Other
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

NCT04096157
View directory record Official record
Conditions
Healthy Subjects
Interventions
Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

NCT05755932
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
HFO-1234ze(E), HFA-134a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

NCT06107205
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
TTYP01, Radicava, Radicava ORS
Drug
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

NCT03457727
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

NCT04235270
View directory record Official record
Conditions
Healthy
Interventions
FDC of Macitentan and Tadalafil, Macitentan, Tadalafil
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 21, 2026, 2:26 AM EDT
Completed No phase listed Observational

Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation

NCT02248779
View directory record Official record
Conditions
Childhood Cancer Survivors Treated With Abdominal Radiation
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 21, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)

NCT07776665
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 21, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 21, 2026, 2:26 AM EDT